Isomorphic Labs Raises $2.1 Billion in Series B to Scale AI Drug Design Engine

On May 12, 2026, Isomorphic Labs, the AI-first drug design company spun out of Google DeepMind, announced a $2.1 billion Series B funding round led by Thrive Capital with participation from Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund to expand its IsoDDE platform and advance its therapeutic pipeline.

Tech Insights Reporter May 12, 2026 6 min read London, UK

TLDR

Isomorphic Labs raised $2.1 billion in Series B funding on May 12, 2026. The round was led by Thrive Capital and included existing investors Alphabet and GV along with new backers MGX (Abu Dhabi), Temasek (Singapore), CapitalG, and the UK Sovereign AI Fund. The capital will scale the company’s AI drug design engine (IsoDDE), expand global operations, and progress drug candidates toward clinical trials across multiple therapeutic areas and modalities.

Company Background and Technology

Founded with the goal of reimagining drug discovery using AI, Isomorphic Labs applies its IsoDDE (Isomorphic Drug Design Engine) — a unified AI system that predicts biomolecular structures, binding affinities, and novel candidates for small molecules, biologics, and antibodies. The platform builds on advances from AlphaFold and related work at DeepMind. The company has partnerships with major biopharma players and maintains an internal pipeline focused on oncology and immunology.

Funding Details and Use of Proceeds

Amount: $2.1 billion Series B.
Lead: Thrive Capital.
Participants: Thrive Capital (lead), Alphabet, GV (existing), MGX, Temasek, CapitalG, UK Sovereign AI Fund (new).
Purpose: Scale the IsoDDE engine, drive global expansion (hiring in AI, engineering, clinical roles across London, Cambridge, and other hubs), and advance drug candidate pipeline into clinical development.

Sir Demis Hassabis, Founder and CEO, noted the round as a significant vote of confidence in the AI-first approach, enabling the team to build out the drug design engine at scale.

Ruth Porat (Alphabet/Google) highlighted the profound opportunity of applying AI in healthcare to bring important interventions to market faster.

Strategic Significance

The raise follows a prior $600 million external round and underscores strong investor interest in AI-native approaches to regulated scientific domains. It expands Isomorphic Labs’ capital base internationally and supports ambitions to deliver biomedical breakthroughs more rapidly than traditional methods.

Why this story matters

This is one of the largest biotech funding rounds to date and demonstrates continued conviction in AI’s ability to transform the historically slow and expensive drug discovery process. With participation from sovereign wealth and government AI funds alongside top VCs and Alphabet, it highlights global strategic interest in AI for life sciences. The scale of capital will test whether frontier AI models can meaningfully compress timelines from target identification to clinical candidates.

Sources

Isomorphic Labs official announcement (isomorphiclabs.com/articles/isomorphic-labs-announces-series-b-investment-round, May 12, 2026): primary details on amount, investors, IsoDDE, pipeline goals, and leadership quotes.
PR Newswire release (May 12, 2026).
Bloomberg and Fierce Biotech coverage (May 12) confirming terms and context.

Featured Image Alt Text

Isomorphic Labs logo with AI molecular structure visualization and funding round graphics highlighting $2.1 billion Series B investors including Thrive Capital and Alphabet.